MX2010002900A - Derivados heterociclicos triciclicos. - Google Patents

Derivados heterociclicos triciclicos.

Info

Publication number
MX2010002900A
MX2010002900A MX2010002900A MX2010002900A MX2010002900A MX 2010002900 A MX2010002900 A MX 2010002900A MX 2010002900 A MX2010002900 A MX 2010002900A MX 2010002900 A MX2010002900 A MX 2010002900A MX 2010002900 A MX2010002900 A MX 2010002900A
Authority
MX
Mexico
Prior art keywords
tricyclic heterocyclic
heterocyclic derivatives
present
relates
serotonin
Prior art date
Application number
MX2010002900A
Other languages
English (en)
Inventor
Grant Wishart
Takao Kiyoi
Peter Christopher Ray
Simon James Anthony Grove
Ashvinkumar Dhirubhai Mistry
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv filed Critical Organon Nv
Publication of MX2010002900A publication Critical patent/MX2010002900A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a un derivado heterocíclico tricíclico de la fórmula (I) en donde las variables son según lo definido en la especificación. La presente invención adicionalmente se refiere a composiciones farmacéuticas que comprenden estos compuestos y a su uso en terapia, particularmente para el tratamiento de trastornos mediados por serotonina tal como obesidad, esquizofrenia y disfunción cognoscitiva.
MX2010002900A 2007-09-17 2008-09-15 Derivados heterociclicos triciclicos. MX2010002900A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07116561 2007-09-17
PCT/EP2008/062229 WO2009037220A1 (en) 2007-09-17 2008-09-15 Tricyclic heterocyclic derivatives

Publications (1)

Publication Number Publication Date
MX2010002900A true MX2010002900A (es) 2010-03-31

Family

ID=39718515

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002900A MX2010002900A (es) 2007-09-17 2008-09-15 Derivados heterociclicos triciclicos.

Country Status (17)

Country Link
US (1) US20100210680A1 (es)
EP (1) EP2203454A1 (es)
JP (1) JP5447380B2 (es)
KR (1) KR20100072027A (es)
CN (1) CN101801980B (es)
AR (1) AR068521A1 (es)
AU (1) AU2008300607B2 (es)
BR (1) BRPI0816992A2 (es)
CA (1) CA2698436A1 (es)
CL (1) CL2008002767A1 (es)
CO (1) CO6260138A2 (es)
MX (1) MX2010002900A (es)
NZ (1) NZ583627A (es)
PE (1) PE20090704A1 (es)
RU (1) RU2010115337A (es)
TW (1) TW200924752A (es)
WO (1) WO2009037220A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546377B2 (en) 2009-04-23 2013-10-01 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
US8518933B2 (en) 2009-04-23 2013-08-27 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
AU2010249472B2 (en) 2009-05-22 2015-09-10 AbbVie Deutschland GmbH & Co. KG Modulators of 5-HT receptors and methods of use thereof
WO2011146089A1 (en) * 2010-05-21 2011-11-24 Abbott Laboratories Modulators of 5-ht receptors and methods of use thereof
US20130267500A1 (en) 2010-09-01 2013-10-10 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
US20120309796A1 (en) 2011-06-06 2012-12-06 Fariborz Firooznia Benzocycloheptene acetic acids
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
AU2019232437A1 (en) 2018-03-07 2020-10-08 Bayer Aktiengesellschaft Identification and use of ERK5 inhibitors
WO2024091983A1 (en) * 2022-10-25 2024-05-02 Artus Therapeutics, Inc. Therapeutic agents for enhancing epithelial and/or endothelial barrier function

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4132709A (en) * 1976-12-20 1979-01-02 Ayerst, Mckenna & Harrison, Ltd. [2]Benzopyrano[4,3-c]pyridine derivatives and process therefor
US4132710A (en) * 1976-12-20 1979-01-02 Ayerst, Mckenna And Harrison, Ltd. [2]Benzopyrano[3,4-c]pyridines and process therefor
NL8005754A (nl) * 1980-10-18 1982-05-17 Akzo Nv Benzo 4,5 pyrano 2,3-c pyrrool derivaten.
US4666916A (en) * 1985-11-08 1987-05-19 Ciba-Geigy Corporation Hexahydro-(1)-benzo-(pyrano and thiopyrano) (4,3-C)pyridines, useful as serotin-2 blocking agents
KR910700251A (ko) * 1988-12-15 1991-03-14 원본미기재 5-ht 선택제
US5049564A (en) * 1989-11-17 1991-09-17 Abbott Laboratories 5-HT selective agents
GB8917333D0 (en) * 1989-07-28 1989-09-13 Merck Sharp & Dohme Therapeutic agents
AU2559392A (en) * 1991-10-24 1993-05-21 Upjohn Company, The Benzo-isoquinoline derivatives and analogs and their use in therapeutics
FR2722194B1 (fr) * 1994-07-06 1996-08-23 Adir Nouveaux derives de benzopyrane, leur procede de preparation et les compositions pharmacuetiques qui les contiennent

Also Published As

Publication number Publication date
KR20100072027A (ko) 2010-06-29
CA2698436A1 (en) 2009-03-26
TW200924752A (en) 2009-06-16
WO2009037220A1 (en) 2009-03-26
US20100210680A1 (en) 2010-08-19
CN101801980A (zh) 2010-08-11
AR068521A1 (es) 2009-11-18
CN101801980B (zh) 2014-03-12
BRPI0816992A2 (pt) 2015-03-24
CO6260138A2 (es) 2011-03-22
RU2010115337A (ru) 2011-10-27
CL2008002767A1 (es) 2009-03-06
JP5447380B2 (ja) 2014-03-19
NZ583627A (en) 2011-08-26
EP2203454A1 (en) 2010-07-07
AU2008300607A1 (en) 2009-03-26
JP2010539139A (ja) 2010-12-16
AU2008300607B2 (en) 2013-08-22
PE20090704A1 (es) 2009-06-20

Similar Documents

Publication Publication Date Title
MX2010002900A (es) Derivados heterociclicos triciclicos.
TN2013000285A1 (en) Novel heterocyclic derivatives and their use in the treatment of neurological disorders
WO2011051490A3 (en) Heterocyclic derivatives
MX2010002353A (es) Amidas heterociclicas utiles para tratamiento de cancer y psoriais.
IN2012DN02968A (es)
SG179034A1 (en) 2 -aminodihydro [1, 3] thiazines as bace 2 inhibitors for the treatment of diabetes
MX2007007103A (es) Derivados espiro como inhibidores de lipoxigenasa.
MX2009006543A (es) Compuestos heterociclicos y su uso en el tratamiento de la inflamacion, angiogenesis y cancer.
MX2011009796A (es) Inhibidores de la cinasa pi3.
MX2012001070A (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurologicos.
MX347423B (es) Derivados de espiro-amina ciclica como moduladores de esfingosina 1 fosfato.
MX2011011335A (es) Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamifero de rapamicina.
MX2014004479A (es) Derivados de oxazina novedosos y su uso en el tratamiento de enfermedades.
NZ577916A (en) Cyclopamine analogs
MX2009010059A (es) Derivados de quinolina para el tratamiento de enfermedades inflamatorias.
TW200833675A (en) Nicotinamide derivatives
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
IL189191A0 (en) Thiazolyl piperidine derivatives useful as h3 receptor modulators
WO2007035620A3 (en) Carbazole derivatives
GEP20135806B (en) Lactams as beta secretase inhibitors
CR9347A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
MX2010013682A (es) Derivados de 2,4-diamino-l,3,5-triazina triciclicos utiles para el tratamiento del cancer y trastornos mieloproliferativos.
MX2009009466A (es) Compuestos triciclicos de utilidad en el tratamiento de trastornos del hierro.
TW200637817A (en) 5-aminoindole derivatives
MY183111A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators

Legal Events

Date Code Title Description
FA Abandonment or withdrawal